NEW DATA ON USE OF PEGASYS FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
MPNRF | April 30, 2021
June 20, 2013
Past MPN Research Foundation grantees Srdan Verstovsek and Ross Levine contributed to a paper recently published by the American Society of Hematology which reports on a study of PV and ET patients treated with pegylated interferon alpha-2a, commonly known as Pegasys. Click here for the abstract and to read the full study.
Pegasys is a treatment that some MPN patients have found useful, though it is not always covered by insurance. For a history of how the Foundation has assisted patients with getting this medication covered click here.